KR20220007105A - 특정 vmat2 억제제의 투여 방법 - Google Patents

특정 vmat2 억제제의 투여 방법 Download PDF

Info

Publication number
KR20220007105A
KR20220007105A KR1020217039903A KR20217039903A KR20220007105A KR 20220007105 A KR20220007105 A KR 20220007105A KR 1020217039903 A KR1020217039903 A KR 1020217039903A KR 20217039903 A KR20217039903 A KR 20217039903A KR 20220007105 A KR20220007105 A KR 20220007105A
Authority
KR
South Korea
Prior art keywords
patient
parkinson
vmat2 inhibitor
symptoms
signs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217039903A
Other languages
English (en)
Korean (ko)
Inventor
다오 투옛 타이-쿠아르토
바바라 숄츠
그레이스 에스. 량
아이리 더블유. 로버츠
Original Assignee
뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로크린 바이오사이언시즈 인코퍼레이티드 filed Critical 뉴로크린 바이오사이언시즈 인코퍼레이티드
Publication of KR20220007105A publication Critical patent/KR20220007105A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020217039903A 2019-05-09 2020-05-08 특정 vmat2 억제제의 투여 방법 Ceased KR20220007105A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845599P 2019-05-09 2019-05-09
US62/845,599 2019-05-09
PCT/US2020/032188 WO2020227672A1 (en) 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors

Publications (1)

Publication Number Publication Date
KR20220007105A true KR20220007105A (ko) 2022-01-18

Family

ID=70919120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039903A Ceased KR20220007105A (ko) 2019-05-09 2020-05-08 특정 vmat2 억제제의 투여 방법

Country Status (17)

Country Link
US (2) US20200397779A1 (https=)
EP (1) EP3965764A1 (https=)
JP (2) JP2022531696A (https=)
KR (1) KR20220007105A (https=)
CN (1) CN114340624A (https=)
AU (2) AU2020270145A1 (https=)
BR (1) BR112021020709A2 (https=)
CA (1) CA3136466A1 (https=)
EA (1) EA202193012A1 (https=)
IL (2) IL321020A (https=)
JO (1) JOP20210274A1 (https=)
MA (1) MA55893A (https=)
MX (1) MX2021013132A (https=)
PH (1) PH12021552745A1 (https=)
SG (1) SG11202111465RA (https=)
TW (1) TWI850377B (https=)
WO (1) WO2020227672A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
CA3220946A1 (en) * 2021-06-30 2023-01-05 Angel S. Angelov Valbenazine for use in the add-on treatment of schizophrenia
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法
EP4489754A1 (en) * 2022-03-07 2025-01-15 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
WO2025038959A1 (en) * 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) * 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025188830A1 (en) * 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US952A (en) 1838-09-27 I antoni bengini
US10065A (en) 1853-10-04 Improvement in machines for topping cotton jn the field
NZ725826A (en) * 2014-05-06 2023-05-26 Neurocrine Biosciences Inc Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
KR20240125709A (ko) * 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MA53239A (fr) * 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2

Also Published As

Publication number Publication date
WO2020227672A1 (en) 2020-11-12
TW202108138A (zh) 2021-03-01
JOP20210274A1 (ar) 2023-01-30
US20200397779A1 (en) 2020-12-24
MA55893A (fr) 2022-03-16
PH12021552745A1 (en) 2022-07-11
AU2025256123A1 (en) 2025-11-13
EA202193012A1 (ru) 2022-03-02
IL321020A (en) 2025-07-01
MX2021013132A (es) 2021-11-25
US20220040169A1 (en) 2022-02-10
CN114340624A (zh) 2022-04-12
JP2025013963A (ja) 2025-01-28
BR112021020709A2 (pt) 2021-12-14
CA3136466A1 (en) 2020-11-12
AU2020270145A1 (en) 2021-12-23
EP3965764A1 (en) 2022-03-16
IL287902A (en) 2022-01-01
SG11202111465RA (en) 2021-11-29
JP2022531696A (ja) 2022-07-08
TWI850377B (zh) 2024-08-01

Similar Documents

Publication Publication Date Title
JP7603662B2 (ja) 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法
KR20220007105A (ko) 특정 vmat2 억제제의 투여 방법
US11026931B2 (en) Methods for the administration of certain VMAT2 inhibitors
TW202345830A (zh) 特定vmat2抑制劑的投予方法
HK40068979A (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
HK40068979B (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
WO2025038959A1 (en) Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601